| Identification | Back Directory | [Name]
TocilizuMab | [CAS]
375823-41-9 | [Synonyms]
R 1569
Actemra
Atlizumab
RoActemra
TocilizuMab
Actemra 200
Tocilizumab-Actemra
Tocilizumab,Atlizumab
anti-IL-6R Tocilizumab
Tocilizumab (anti-IL-6R) | [EINECS(EC#)]
248-451-4 | [Molecular Formula]
C14H12O3 | [MDL Number]
MFCD01633115 |
| Hazard Information | Back Directory | [Clinical Use]
Interleukin inhibitor:
Treatment of rheumatoid arthritis in combination with methotrexate | [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant administration | [Metabolism]
Tocilizumab undergoes biphasic elimination from the circulation. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear and non-linear clearance. The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations. Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance. | [storage]
Store at -80°C |
|
|